Editorial
Consolidative ablative radiotherapy improves outcomes in oligometastatic non-small cell lung cancer: a further step toward new evidence
Abstract
Lung cancer is associated with the worst cancer-specific survival than any other tumor. Most of the patients with non-small cell lung cancer (NSCLC) are diagnosed in IV Stage or will develop metastatic progression during the course of the disease (1). A paucity of treatments warrant durable survival benefits once the tumor has spread over the lungs, likely due to the aggressive nature and the ability to progress.